Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial

J M N Lopes Cardozo,D Byng, C A Drukker,M K Schmidt, M A Binuya,L J van 't Veer,F Cardoso,M Piccart,C H Smorenburg, C Poncet,E J T Rutgers

Annals of Oncology（2022）

引用 8|浏览6

暂无评分

摘要

•Patients who received no AST had a 2.5% lower 8-year DMFI rate than that observed in matched patients who received ET.•Slightly more locoregional recurrences and contralateral breast cancers were observed in patients who received no AST.•These effects and side-effects of ET should be discussed with patients even at a very low risk of distant metastasis.

查看译文

关键词

low-risk breast cancer,no adjuvant systemic treatment,endocrine therapy,breast cancer recurrence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要